About US
Contact us
-
J&J, Lilly and AZ diabetes medications get another helping of real-world heart benefitsLast year, real-world data showed that SGLT2 diabetes drugs could significantly cut heart failure hospitalizations and all-cause deaths. And now, a new analysis shows they can also cut the rate of maj2017/11/22
-
Not over till it’s over: Pharma ad police issue another warning, this time to Amherst and MagnaIt turns out pharma's ad police aren't done doling out warnings in a year that's seen a historic few. The FDA's Office of Prescription Drug Promotion issued another warning last week, bringing its tot2017/11/22
-
Concordia catches antitrust scrutiny over 5,700% price rise for thyroid drugConcordia Healthcare has already caught the ire of government watchdogs and pharmacy benefits managers for its price hikes. Now, add one more investigation to its list: A U.K.antitrust probeinto its p2017/11/21
-
With $2.5B in Herceptin sales on the line, Roche sues Pfizer for biosim patent infringementBringing biosimilars to market isn't an easy proposition, as Pfizer and its fellow biosimilar makers continue to discover. In another hurdle Pfizer will have to clear, Roche has sued for infringement2017/11/21
-
Intense EMA campaign ends in chance: Amsterdam selected for HQ over Milan after a tieWith all eyes fixed on Monday's vote for the European Medicines Agency relocation, Amsterdam emerged as thewinnerfor the new headquarters ahead of other finalists Milan and Copenhagen. Nineteen E2017/11/20
-
Pfizer in fight with states over their intent to use its drugs for executionsPfizer is in a tug of war with several states that intend to use some of its drugs to carry out executions. The drugmaker sent letters last month to both Nevada and Nebraska asking for the return o2017/11/20
-
J&J notches latest win in long-running talc saga as caseload grows to 5,500As the number of pending talc cases continues to tick upward, Johnson & Johnson is maintaining its defensive winning streak. On Thursday, jurors in Los Angeles sided with the company against a pla2017/11/17
-
Pfizer’s Sutent kidney cancer win should give it a boost, at least until I-O treatments arrivePfizer’s old dog Sutent has shown it has one more trick to perform as a renal cancer treatmentbefore being passed up by the new breed of immuno-oncology drugs. Despite misgivings by an FDA advisory2017/11/17
-
Roche nabs blockbuster FDA approval for Hemlibra, big label expansion for GazyvaCall it a big day for Roche at the FDA, as the drug giant picked up two critical approvals on Thursday, firstfor hemophilia A drug Hemlibra and then with a label expansion for Gazyva. Hemlibrawon2017/11/16
-
Lilly used nursing services as kickbacks to boost insulin prescriptions, lawsuit claimsAfter Novo Nordisk settled a lawsuit alleging it marketed certain drugs under a "white coat" sales scheme, fellow diabetes drug giant Eli Lilly is facing similar claims of illicit marketing. A recen2017/11/16